Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 Apr;77(7):1048–1051. doi: 10.1038/bjc.1998.175

Evaluation of FHIT gene alterations in ovarian cancer.

F Buttitta 1, A Marchetti 1, O Radi 1, G Bertacca 1, S Pellegrini 1, A Gadducci 1, A R Genazzani 1, G Bevilacqua 1
PMCID: PMC2150139  PMID: 9569038

Abstract

The FHIT gene, recently cloned and mapped on chromosome 3p14.2, has frequently been found to be abnormal in several established cancer cell lines and primary tumours. As alterations of chromosome 3p are common events in ovarian cancers with breakpoint sites at 3p14.2, we decided to investigate the role of FHIT in human ovarian tumorigenesis. Fifty-four primary ovarian carcinomas were studied by reverse transcription of FHIT mRNA followed by polymerase chain reaction (PCR) amplification and sequencing of products. The same tumours and matched normal tissues were also investigated for loss of heterozygosity using three microsatellite markers located inside the gene. We found an abnormal transcript of the FHIT gene in two cases (4%) and allelic losses in eight cases (15%). Twelve (22%) of the 54 tumours investigated belonged to young patients with a family history of breast/ovarian cancer. In none of these cases was the FHITgene found to be altered. Our results indicate that FHITplays a role in a small proportion of ovarian carcinomas.

Full text

PDF
1048

Images in this article

1049Figure 1
on p.1049
1050Figure 2
on p.1050

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Barnes L. D., Garrison P. N., Siprashvili Z., Guranowski A., Robinson A. K., Ingram S. W., Croce C. M., Ohta M., Huebner K. Fhit, a putative tumor suppressor in humans, is a dinucleoside 5',5"'-P1,P3-triphosphate hydrolase. Biochemistry. 1996 Sep 10;35(36):11529–11535. doi: 10.1021/bi961415t. [DOI] [PubMed] [Google Scholar]
  2. Bosari S., Viale G., Radaelli U., Bossi P., Bonoldi E., Coggi G. p53 accumulation in ovarian carcinomas and its prognostic implications. Hum Pathol. 1993 Nov;24(11):1175–1179. doi: 10.1016/0046-8177(93)90212-y. [DOI] [PubMed] [Google Scholar]
  3. Buttitta F., Marchetti A., Gadducci A., Pellegrini S., Morganti M., Carnicelli V., Cosio S., Gagetti O., Genazzani A. R., Bevilacqua G. p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br J Cancer. 1997;75(2):230–235. doi: 10.1038/bjc.1997.38. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Cliby W., Ritland S., Hartmann L., Dodson M., Halling K. C., Keeney G., Podratz K. C., Jenkins R. B. Human epithelial ovarian cancer allelotype. Cancer Res. 1993 May 15;53(10 Suppl):2393–2398. [PubMed] [Google Scholar]
  5. Dodson M. K., Hartmann L. C., Cliby W. A., DeLacey K. A., Keeney G. L., Ritland S. R., Su J. Q., Podratz K. C., Jenkins R. B. Comparison of loss of heterozygosity patterns in invasive low-grade and high-grade epithelial ovarian carcinomas. Cancer Res. 1993 Oct 1;53(19):4456–4460. [PubMed] [Google Scholar]
  6. Eccles D. M., Cranston G., Steel C. M., Nakamura Y., Leonard R. C. Allele losses on chromosome 17 in human epithelial ovarian carcinoma. Oncogene. 1990 Oct;5(10):1599–1601. [PubMed] [Google Scholar]
  7. Ehlen T., Dubeau L. Loss of heterozygosity on chromosomal segments 3p, 6q and 11p in human ovarian carcinomas. Oncogene. 1990 Feb;5(2):219–223. [PubMed] [Google Scholar]
  8. Houlston R. S., Collins A., Slack J., Campbell S., Collins W. P., Whitehead M. I., Morton N. E. Genetic epidemiology of ovarian cancer: segregation analysis. Ann Hum Genet. 1991 Oct;55(Pt 4):291–299. doi: 10.1111/j.1469-1809.1991.tb00856.x. [DOI] [PubMed] [Google Scholar]
  9. Huang Y., Garrison P. N., Barnes L. D. Cloning of the Schizosaccharomyces pombe gene encoding diadenosine 5',5"'-P1,P4-tetraphosphate (Ap4A) asymmetrical hydrolase: sequence similarity with the histidine triad (HIT) protein family. Biochem J. 1995 Dec 15;312(Pt 3):925–932. doi: 10.1042/bj3120925. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Islam M. Q., Köpf I., Levan A., Granberg S., Friberg L. G., Levan G. Cytogenetic findings in 111 ovarian cancer patients: therapy-related chromosome aberrations and heterochromatic variants. Cancer Genet Cytogenet. 1993 Jan;65(1):35–46. doi: 10.1016/0165-4608(93)90056-r. [DOI] [PubMed] [Google Scholar]
  11. Jenkins R. B., Bartelt D., Jr, Stalboerger P., Persons D., Dahl R. J., Podratz K., Keeney G., Hartmann L. Cytogenetic studies of epithelial ovarian carcinoma. Cancer Genet Cytogenet. 1993 Nov;71(1):76–86. doi: 10.1016/0165-4608(93)90205-z. [DOI] [PubMed] [Google Scholar]
  12. Jones M. H., Nakamura Y. Deletion mapping of chromosome 3p in female genital tract malignancies using microsatellite polymorphisms. Oncogene. 1992 Aug;7(8):1631–1634. [PubMed] [Google Scholar]
  13. Kastury K., Baffa R., Druck T., Ohta M., Cotticelli M. G., Inoue H., Negrini M., Rugge M., Huang D., Croce C. M. Potential gastrointestinal tumor suppressor locus at the 3p14.2 FRA3B site identified by homozygous deletions in tumor cell lines. Cancer Res. 1996 Mar 1;56(5):978–983. [PubMed] [Google Scholar]
  14. Kupryjańczyk J., Thor A. D., Beauchamp R., Merritt V., Edgerton S. M., Bell D. A., Yandell D. W. p53 gene mutations and protein accumulation in human ovarian cancer. Proc Natl Acad Sci U S A. 1993 Jun 1;90(11):4961–4965. doi: 10.1073/pnas.90.11.4961. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Leary J.A., Doris C.P., Boltz E.M., Houghton C.R.S., Kefford R.F., Friedlander M.L. Investigation of loss of heterozygosity at specific loci on chromosomes 3p, 6q, 11p, 17p and 17q in ovarian cancer. Int J Gynecol Cancer. 1993 Sep;3(5):293–298. doi: 10.1046/j.1525-1438.1993.03050293.x. [DOI] [PubMed] [Google Scholar]
  16. Marchetti A., Buttitta F., Merlo G., Diella F., Pellegrini S., Pepe S., Macchiarini P., Chella A., Angeletti C. A., Callahan R. p53 alterations in non-small cell lung cancers correlate with metastatic involvement of hilar and mediastinal lymph nodes. Cancer Res. 1993 Jun 15;53(12):2846–2851. [PubMed] [Google Scholar]
  17. Negrini M., Monaco C., Vorechovsky I., Ohta M., Druck T., Baffa R., Huebner K., Croce C. M. The FHIT gene at 3p14.2 is abnormal in breast carcinomas. Cancer Res. 1996 Jul 15;56(14):3173–3179. [PubMed] [Google Scholar]
  18. Non-surgical aspects of ovarian cancer. Lancet. 1994 Feb 5;343(8893):335–340. [PubMed] [Google Scholar]
  19. Ohta M., Inoue H., Cotticelli M. G., Kastury K., Baffa R., Palazzo J., Siprashvili Z., Mori M., McCue P., Druck T. The FHIT gene, spanning the chromosome 3p14.2 fragile site and renal carcinoma-associated t(3;8) breakpoint, is abnormal in digestive tract cancers. Cell. 1996 Feb 23;84(4):587–597. doi: 10.1016/s0092-8674(00)81034-x. [DOI] [PubMed] [Google Scholar]
  20. Osborne R. J., Leech V. Polymerase chain reaction allelotyping of human ovarian cancer. Br J Cancer. 1994 Mar;69(3):429–438. doi: 10.1038/bjc.1994.79. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Russell S. E., Hickey G. I., Lowry W. S., White P., Atkinson R. J. Allele loss from chromosome 17 in ovarian cancer. Oncogene. 1990 Oct;5(10):1581–1583. [PubMed] [Google Scholar]
  22. Sanchez Y., el-Naggar A., Pathak S., Killary A. M. A tumor suppressor locus within 3p14-p12 mediates rapid cell death of renal cell carcinoma in vivo. Proc Natl Acad Sci U S A. 1994 Apr 12;91(8):3383–3387. doi: 10.1073/pnas.91.8.3383. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Shelling A. N., Cooke I. E., Ganesan T. S. The genetic analysis of ovarian cancer. Br J Cancer. 1995 Sep;72(3):521–527. doi: 10.1038/bjc.1995.367. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Shridhar R., Shridhar V., Wang X., Paradee W., Dugan M., Sarkar F., Wilke C., Glover T. W., Vaitkevicius V. K., Smith D. I. Frequent breakpoints in the 3p14.2 fragile site, FRA3B, in pancreatic tumors. Cancer Res. 1996 Oct 1;56(19):4347–4350. [PubMed] [Google Scholar]
  25. Sozzi G., Alder H., Tornielli S., Corletto V., Baffa R., Veronese M. L., Negrini M., Pilotti S., Pierotti M. A., Huebner K. Aberrant FHIT transcripts in Merkel cell carcinoma. Cancer Res. 1996 Jun 1;56(11):2472–2474. [PubMed] [Google Scholar]
  26. Sozzi G., Veronese M. L., Negrini M., Baffa R., Cotticelli M. G., Inoue H., Tornielli S., Pilotti S., De Gregorio L., Pastorino U. The FHIT gene 3p14.2 is abnormal in lung cancer. Cell. 1996 Apr 5;85(1):17–26. doi: 10.1016/s0092-8674(00)81078-8. [DOI] [PubMed] [Google Scholar]
  27. Thiagalingam S., Lisitsyn N. A., Hamaguchi M., Wigler M. H., Willson J. K., Markowitz S. D., Leach F. S., Kinzler K. W., Vogelstein B. Evaluation of the FHIT gene in colorectal cancers. Cancer Res. 1996 Jul 1;56(13):2936–2939. [PubMed] [Google Scholar]
  28. Thompson F. H., Emerson J., Alberts D., Liu Y., Guan X. Y., Burgess A., Fox S., Taetle R., Weinstein R., Makar R. Clonal chromosome abnormalities in 54 cases of ovarian carcinoma. Cancer Genet Cytogenet. 1994 Mar;73(1):33–45. doi: 10.1016/0165-4608(94)90179-1. [DOI] [PubMed] [Google Scholar]
  29. Zheng J. P., Robinson W. R., Ehlen T., Yu M. C., Dubeau L. Distinction of low grade from high grade human ovarian carcinomas on the basis of losses of heterozygosity on chromosomes 3, 6, and 11 and HER-2/neu gene amplification. Cancer Res. 1991 Aug 1;51(15):4045–4051. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES